Back to Newsroom
Back to Newsroom

Lawsuits Filed Against WISH, OCGN and DKNG - Jakubowitz Law Pursues Shareholders Claims

Thursday, 15 July 2021 05:40 AM

Jakubowitz Law

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / July 15, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Contextlogic Inc. (NASDAQ:WISH)

CONTACT JAKUBOWITZ ABOUT WISH:
https://claimyourloss.com/securities/contextlogic-inc-loss-submission-form/?id=17670&from=1

This lawsuit is on behalf of investors who purchased WISH pursuant or traceable to the registration statement and prospectus issued in connection with ContextLogic's December 16, 2020 initial public stock offering or between December 16, 2020 and May 12, 2021.

Lead Plaintiff Deadline : July 16, 2021

In the registration statement and prospectus used to conduct the initial public offering and throughout the class period, defendants made materially false and misleading statements about the strength of ContextLogic's business operations and financial prospects by overstating its then-present monthly active users ("MAUs") and MAU growth trends.

Ocugen, Inc. (NASDAQ:OCGN)

CONTACT JAKUBOWITZ ABOUT OCGN:
https://claimyourloss.com/securities/ocugen-inc-loss-submission-form/?id=17670&from=1

Class Period: February 2, 2021 - June 10, 2021

Lead Plaintiff Deadline: August 17, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the information submitted to the U.S. Food and Drug Administration ("FDA") was insufficient to support an Emergency Use Authorization ("EUA"), (ii) Ocugen would not file an EUA with the FDA, (iii) as a result of the foregoing, the Company's financial statements, as well as Defendants' statements about Ocugen's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

DraftKings Inc. f/k/a Diamond Eagle Acquisition Corp. (NASDAQ:DKNG)

CONTACT JAKUBOWITZ ABOUT DKNG:
https://claimyourloss.com/securities/draftkings-inc-f-k-a-diamond-eagle-acquisition-corp-loss-submission-form/?id=17670&from=1

Class Period: December 23, 2019 - June 15, 2021

Lead Plaintiff Deadline: August 31, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) SBTech Global Limited ("SBTech"), a company acquired by DraftKings, had a history of unlawful operations; (ii) accordingly, DraftKings' merger with SBTech exposed the Company to dealings in black-market gaming; (iii) the foregoing increased the Company's regulatory and criminal risks with respect to these transactions; (iv) as a result of all the foregoing, the Company's revenues were, in part, derived from unlawful conduct and thus unsustainable; (v) accordingly, the benefits of the Business Combination were overstated; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Jakubowitz Law, Thursday, July 15, 2021, Press release picture

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: